Etemadifar M, Janghorbani M, Shaygannejad V
Department of Neurology and Epidemiology, Isfahan University of Medical Sciences and Health Services, Isfahan, Iran.
Acta Neurol Scand. 2006 May;113(5):283-7. doi: 10.1111/j.1600-0404.2006.00585.x.
To compare the relative efficacies of Betaferon, Avonex, and Rebif in the treatment of relapsing-remitting multiple sclerosis (RRMS).
Ninety patients with RRMS were randomly allocated to the three treatment groups. The first group received Betaferon, the second group received Avonex, and the third group received Rebif for 24 months. Response to treatment was assessed at 6, 12, and 24 months after start of therapy.
Of the 30 patients treated with Betaferon, the mean (standard deviation, SD) of relapse rate decreased from 2.2 (0.7) to 0.7 (0.7) episodes. Correspondingly, in the 30 patients treated with Avonex, the mean (SD) of relapse rate decreased from 2.0 (1.2) to 1.2 (0.9) (P < 0.001). In the 30 patients treated with Rebif, the mean (SD) of relapse rate decreased from 2.4 (1.0) to 0.6 (0.9) (P < 0. 01). After 2 years, 43.3% of patients receiving Betaferon and 56.7% of patients receiving Rebif remained relapse-free compared with 20% of those given Avonex. Expanded Disability Status Scale (EDSS) decreased by 0.7 U in Betaferon-treated patients (P < 0.001), 0.3 U in Rebif-treated patients (P < 0.05), and remained stable in Avonex patients.
Treatment with Betaferon, Avenox, and Rebif significantly reduce relapse rate and EDSS score in patients with RRMS.
比较β-干扰素、阿沃尼克斯和利比治疗复发缓解型多发性硬化症（RRMS）的相对疗效。
90例RRMS患者被随机分配到三个治疗组。第一组接受β-干扰素治疗，第二组接受阿沃尼克斯治疗，第三组接受利比治疗，为期24个月。在治疗开始后的6个月、12个月和24个月评估治疗反应。
在接受β-干扰素治疗的30例患者中，复发率的均值（标准差，SD）从2.2（0.7）降至0.7（0.7）次发作。相应地，在接受阿沃尼克斯治疗的30例患者中，复发率的均值（SD）从2.0（1.2）降至1.2（0.9）（P<0.001）。在接受利比治疗的30例患者中，复发率的均值（SD）从2.4（1.0）降至0.6（0.9）（P<0.01）。2年后，接受β-干扰素治疗的患者中有43.3%、接受利比治疗的患者中有56.7%保持无复发，而接受阿沃尼克斯治疗的患者中这一比例为20%。接受β-干扰素治疗的患者扩展残疾状态量表（EDSS）下降了0.7个单位（P<0.001），接受利比治疗的患者下降了0.3个单位（P<0.05），接受阿沃尼克斯治疗的患者EDSS保持稳定。
β-干扰素、阿沃尼克斯和利比治疗可显著降低RRMS患者的复发率和EDSS评分。
